Benfotiamine in Alzheimer's Disease
Testing the benefits of the vitamin supplement Benfotiamine in patients with Alzheimer's Disease
Sponsor: National Institute on Aging, Alzheimer's Drug Discovery
Enrolling: Male and Female Patients
Study Length: 12 Months
Clinic Visits: 7
IRB Number: AAAO7103
U.S. Govt. ID: NCT02292238
Contact: Yaakov Stern, PhD: 212-342-1350 / ys11@cumc.columbia.edu
Additional Study Information: The goal of this study is to investigate whether treatment with the vitamin supplement benfotiamine for one year will slow the memory problems in patients who meet the definition of Alzheimer's disease or amnestic mild cognitive impairment, an early manifestation of Alzheimer's disease.
This study is closed
Investigator
Yaakov Stern, PhD
Do You Qualify?
Do you suffer from memory problems? Yes No
Are you 65 years of age or older? Yes No
Do you speak English? Yes No
Do you have a companion available for visits? Yes No
Are you living in a community home? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Yaakov Stern, PhD
ys11@cumc.columbia.edu
212-342-1350
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE